Kapitel 78: Multiples Myelom


Blade J, Sureda A, Ribera JM et al. (2003) High dose therapy/autotransplantation/intensification versus continued conventional chemotherapy in multiple myeloma patients responding to initial chemotherapy. Definitive results from Pethema after a median follow-up of 66 months (abstract). Blood 102: 42a


Davies FE, Rollinson SJ, Rawstron AC et al. (2000) High-producer haplotypes of tumor necrosis factor alpha and lympho toxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment. J Clin Oncol 18: 2843–2851


Fermand JP, Ravaud P, Katsahian S et al. (1999) High dose therapy and autologous blood stem cell transplantation versus conventional treatment in multiple myeloma: Results of a randomized trial in 190 patients 55 to 65 years of age (abstract). Blood 94 (suppl1): 396a


Hose D, Rossi J-F, Ittrich C et al. (2005) Molecular classification of multiple myeloma (MM) based on gene expression profiling (GEP) and fluorescence in situ hybridisation (FISH) is an independent predictor for event free survival (EFS). Blood 106: 150a


Kiel K, Cremer FW, Rottenburger C et al. (1999) Analysis of circulating tumor cells in patients with multiple myeloma during the course of high-dose therapy with peripheral blood stem cell transplantation. Bone Marrow Transplant 23: 1019–1027


Hanamura, Stewart P, Cavallo F et al. (2005) Frequent gains of chromosome arm 1q21 in plasma cell dyscrasia detected by fluorescence in situ hybridization: Incidence increases from MGUS to relapsed myeloma and is related to disease progression and prognosis., 106 edn pp 445a-446a


Weber D, Wang C, Chen C et al. (2007) Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of 2 phase III studies (MM-009, MM-010) and subgroup analysis of patients with impaired renal function. Blood 108: 1012a


Zhan, Barlogie B, Huang Y et al. (2004) The transcriptome of multiple myeloma (MM) defines disease subgroups with distinct genetic and clinical features., 104 edn p 26a